Results from the JAVELIN Ovarian 200 biomarker analysis

Eric Pujade-Lauraine, MD, PhD, Hôpital Hôtel-Dieu, Paris, France, discusses the results of a biomarker analysis of the JAVELIN Ovarian 200 study (NCT02580058), evaluating avelumab combined with pegylated liposomal doxorubicin in platinum-resistant/refractory ovarian cancer. In this exploratory analysis, biomarkers of response were identified in this patient population. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.